The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies von Nahimana, Aimable, Attinger, Antoine, Aubry, Dominique, Greaney, Peter, Ireson, Christopher, Thougaard, Annemette V., Tjørnelund, Jette, Dawson, Keith M., Dupuis, Marc, Duchosal, Michel A.

Volltext

Beyond Antibodies: The DARPin® Drug Platform von Stumpp, Michael T., Dawson, Keith M., Binz, H. Kaspar

Volltext

Beyond Antibodies: The DARPin® Drug Platform von Stumpp, Michael T., Dawson, Keith M., Binz, H. Kaspar

Volltext

A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepat... von Knop, Stefan, Szarejko, Monika, Grząśko, Norbert, Bringhen, Sara, Trautmann‐Grill, Karolin, Jurczyszyn, Artur, Vacca, Angelo, Khandanpour, Cyrus, Gamberi, Barbara, Pour, Ludek, Iversen, Katrine F., Stumpp, Michael T., Suter, Cosima, Dawson, Keith M., Zitt, Christof, Legenne, Philippe, Stavropoulou, Vaia, Fey, Martin F., Leupin, Nicolas, Goldschmidt, Hartmut

Volltext

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors von Baird, Richard D, Linossi, Constanza, Middleton, Mark, Lord, Simon, Harris, Adrian, Rodón, Jordi, Zitt, Christof, Fiedler, Ulrike, Dawson, Keith M, Leupin, Nicolas, Stumpp, Michael T, Harstrick, Andreas, Azaro, Analía, Fischer, Stefanie, Omlin, Aurelius

Volltext

MP0250, a VEGF and HGF neutralizing DARPin ® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models von Fiedler, Ulrike, Ekawardhani, Savira, Cornelius, Andreas, Gilboy, Pat, Bakker, Talitha R, Dolado, Ignacio, Stumpp, Michael T, Dawson, Keith M

Volltext

Abstract 4966: Phospho-proteome analyses confirm the unique mode of action of MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin® drug candidate von Mitra, Vikram, Fiedler, Ulrike, Snell, Dan, Dawson, Keith M., Jung, Stephan, Pike, Ian, Baur, Elmar vom

Volltext

Abstract CT149: MP0250, a VEGF- and HGF-blocking multi-DARPin drug candidate, in combination with tyrosine-kinase-inhibitors targeting EGFR-mutated NSCLC: Preclinical rationale and... von Kiemle-Kallee, Joachim, Fiedler, Ulrike, Dawson, Keith M., Haunschild, Jutta, Dietschy, Sandra, Stumpp, Michael T., Hermann, Frank, Harstrick, Andreas

Volltext

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants von Rothenberger, Sylvia, Hurdiss, Daniel L, Walser, Marcel, Malvezzi, Francesca, Mayor, Jennifer, Ryter, Sarah, Moreno, Hector, Liechti, Nicole, Bosshart, Andreas, Iss, Chloé, Calabro, Valérie, Cornelius, Andreas, Hospodarsch, Tanja, Neculcea, Alexandra, Looser, Thamar, Schlegel, Anja, Fontaine, Simon, Villemagne, Denis, Paladino, Maria, Schiegg, Dieter, Mangold, Susanne, Reichen, Christian, Radom, Filip, Kaufmann, Yvonne, Schaible, Doris, Schlegel, Iris, Zitt, Christof, Sigrist, Gabriel, Straumann, Marcel, Wolter, Julia, Comby, Marco, Sacarcelik, Feyza, Drulyte, Ieva, Lyoo, Heyrhyoung, Wang, Chunyan, Li, Wentao, Du, Wenjuan, Binz, H Kaspar, Herrup, Rachel, Lusvarghi, Sabrina, Neerukonda, Sabari Nath, Vassell, Russell, Wang, Wei, Adler, Julia M, Eschke, Kathrin, Nascimento, Mariana, Abdelgawad, Azza, Gruber, Achim D, Bushe, Judith, Kershaw, Olivia, Knutson, Charles G, Balavenkatraman, Kamal K, Ramanathan, Krishnan, Wyler, Emanuel, Teixeira Alves, Luiz Gustavo, Lewis, Seth, Watson, Randall, Haeuptle, Micha A, Zürcher, Alexander, Dawson, Keith M, Steiner, Daniel, Weiss, Carol D, Amstutz, Patrick, van Kuppeveld, Frank J M, Stumpp, Michael T, Bosch, Berend-Jan, Engler, Olivier, Trimpert, Jakob

Volltext

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants von Rothenberger, Sylvia, Hurdiss, Daniel L, Walser, Marcel, Malvezzi, Francesca, Mayor, Jennifer, Ryter, Sarah, Moreno, Hector, Liechti, Nicole, Bosshart, Andreas, Iss, Chloe, Calabro, Valerie, Cornelius, Andreas, Hospodarsch, Tanja, Neculcea, Alexandra, Looser, Thamar, Schlegel, Anja, Fontaine, Simon, Villemagne, Denis, Paladino, Maria, Schiegg, Dieter, Mangold, Susanne, Reichen, Christian, Radom, Filip, Kaufmann, Yvonne, Schaible, Doris, Schlegel, Iris, Zitt, Christof, Sigrist, Gabriel, Straumann, Marcel, Wolter, Julia, Comby, Marco, Sacarcelik, Feyza, Drulyte, Ieva, Lyoo, Heyrhyoung, Wang, Chunyan, Li, Wentao, Du, Wenjuan, Binz, H. Kaspar, Herrup, Rachel, Lusvarghi, Sabrina, Neerukonda, Sabari Nath, Vassell, Russell, Wang, Wei, Adler, Julia M, Eschke, Kathrin, Nascimento, Mariana, Abdelgawad, Azza, Gruber, Achim D, Bushe, Judith, Kershaw, Olivia, Knutson, Charles G, Balavenkatraman, Kamal K, Ramanathan, Krishnan, Wyler, Emanuel, Alves, Luiz Gustavo Teixeira, Lewis, Seth, Watson, Randall, Haeuptle, Micha A, Zuercher, Alexander, Dawson, Keith M, Steiner, Daniel, Weiss, Carol D, Amstutz, Patrick, van Kuppeveld, Frank J.M, Stumpp, Michael T, Bosch, Berend-Jan, Engler, Olivier, Trimpert, Jakob

Volltext

Abstract 3029: FAP-mediated tumor accumulation of a T-cell agonistic FAP/4-1BB DARPin drug candidate analyzed by SPECT/CT and quantitative biodistribution von Reichen, Christian, Bessey, Ralph, DePasquale, Christine, Imobersteg, Stefan, Behe, Martin, Blanc, Alain, Schibli, Roger, Link, Alexander, Juglair, Laurent, Taylor, Joanna, Schildknecht, Patricia, Hepp, Julia, Baur, Elmar vom, Ji, Hong, Zitt, Christof, Levitsky, Victor, Dawson, Keith M., Stumpp, Michael T., Snell, Dan

Volltext

First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors von Azaro, Analia, Rodon, Jordi, Middleton, Mark R., Baird, Richard D., Herrmann, Richard, Fiedler, Ulrike, Haunschild, Jutta, Häuptle, Micha, Hermann, Frank Jurgen, Schreiner, Sabrina, Harstrick, Andreas, Dawson, Keith M., Omlin, Aurelius Gabriel

Volltext

Comparison of an FAP-targeted, CD137 activating DARPin drug candidate with a non-targeted, CD137 activating antibody in a human PBMC transplanted HT-29 mouse tumor model von Hepp, Julia, Link, Alexander, Fiedler, Ulrike, Reichen, Christian, Metz, Clara, Titz, Alexander, Tosevski, Ivana, Juglair, Laurent, Schildknecht, Patricia, Kaufmann, Yvonne, Fontaine, Simon, Bessey, Ralph, Arany, Zita, Zitt, Christof, Dawson, Keith M., Steiner, Daniel, Snell, Dan, Levitsky, Victor, Stumpp, Michael T.

Volltext

Abstract 3752: Preclinical pharmacology of MP0310: A 4-1BB/FAP bispecific DARPin drug candidate promoting tumor-restricted T-cell costimulation von Link, Alexander, Hepp, Julia, Reichen, Christian, Schildknecht, Patricia, Tosevski, Ivana, Taylor, Joanna, Juglair, Laurent, Titz, Alexander, Matzner, Mirela, Bessey, Ralph, Zitt, Christof, Lemaillet, Guy, Herbst, Joerg, Dawson, Keith M., Ji, Hong, Levitsky, Victor, Snell, Dan, Stumpp, Michael T., Harstrick, Andreas, Baur, Elmar vom

Volltext

Abstract B25: First-in-human Phase I study to evaluate MP0250, a DARPin blocking HGF and VEGF, in patients with advanced solid tumors von Rodon, Jordi, Omlin, Aurelius, Herbschleb, Karin H., Garcia-Corbacho, Javier, Steiner, Jan, Dolado, Ignacio, Zitt, Christof, Feurstein, Daniel, Turner, Dascha, Dawson, Keith M., Stumpp, Michael T., Gilboy, Patrick, Harstrick, Andreas, Azaro, Analía, Ackermann, Christoph J., Middleton, Mark R., Baird, Richard D.

Volltext

The expression of hybrid HIV:Ty virus-like particles in yeast von Adams, Sally E, Dawson, Keith M, Gull, Keith, Kingsman, Susan M, Kingsman, Alan J

Volltext

Type 2 Diabetes Mellitus Management in Canada: Is It Improving? von Leiter, Lawrence A., MD, Berard, Lori, RN, Bowering, C. Keith, MD, Cheng, Alice Y., MD, Dawson, Keith G., MD, Ekoé, Jean-Marie, MD, Fournier, Carl, MD, Goldin, Lianne, Harris, Stewart B., MD, MPH, Lin, Peter, MD, Ransom, Thomas, MD, MSc, Tan, Mary, MSc, Teoh, Hwee, PhD, Tsuyuki, Ross T., PharmD, MSc, Whitham, Dana, RD, MSc, Woo, Vincent, MD, Yale, Jean-François, MD, Langer, Anatoly, MD, MSc

Volltext

Substitution of Arginine 719 for Glutamic Acid in Human Plasminogen Substantially Reduces Its Affinity for Streptokinase von Dawson, Keith M, Marshall, Julian M, Raper, Robert H, Gilbert, Richard J, Ponting, Christopher P

Volltext

Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada von Braga, Manoela F.B., MD, Casanova, Amparo, MD PhD, Teoh, Hwee, PhD, Dawson, Keith G., MD PhD, Gerstein, Hertzel C., MD MSc, Fitchett, David H., MD, Harris, Stewart B., MD MPH, Honos, George, MD, McFarlane, Philip A., MD PhD, Steele, Andrew, MD, Ur, Ehud, MB, Yale, Jean-François, MD, Langer, Anatoly, MD MSc, Goodman, Shaun G., MD MSc, Leiter, Lawrence A., MD

Volltext

The NAD biosynthesis inhibitor AP0866 has potent antitumor activity against hematologic malignancies von NAHIMANA, Aimable, ATTINGER, Antoine, AUBRY, Dominique, GREANEY, Peter, IRESON, Christopher, THOUGAARD, Annemette V, TJØMELUND, Jette, DAWSON, Keith M, DUPUIS, Marc, DUCHOSAL, Michel A

Volltext